Skip to main content

6 Result(s)

within Il Minn Remove this filter Medicine & Public Health Remove this filter

and

  1. No Access

    Article

    First-in-human imaging using [11C]MDTC: a radiotracer targeting the cannabinoid receptor type 2

    We report findings from the first-in-human study of [11C]MDTC, a radiotracer developed to image the cannabinoid receptor type 2 (CB2R) with positron emission tomography (PET).

    Yong Du, Jennifer M. Coughlin… in European Journal of Nuclear Medicine and M… (2023)

  2. Article

    Correction to: Hetero-bivalent agents targeting FAP and PSMA

    Srikanth Boinapally, Alla Lisok… in European Journal of Nuclear Medicine and M… (2022)

    Download PDF (422 KB) View Article

  3. No Access

    Article

    Hetero-bivalent agents targeting FAP and PSMA

    We developed a theranostic radiopharmaceutical that engages two key cell surface proteases, fibroblast activation protein alpha (FAP) and prostate-specific membrane antigen (PSMA), each frequently overexpresse...

    Srikanth Boinapally, Alla Lisok… in European Journal of Nuclear Medicine and M… (2022)

  4. No Access

    Article

    First-in-human neuroimaging of soluble epoxide hydrolase using [18F]FNDP PET

    Soluble epoxide hydrolase (sEH) is an enzyme with putative effect on neuroinflammation through its influence on the homeostasis of polyunsaturated fatty acids and related byproducts. sEH is an enzyme that meta...

    Jennifer M. Coughlin, Stephanie Slania… in European Journal of Nuclear Medicine and M… (2021)

  5. Article

    Open Access

    PET imaging of soluble epoxide hydrolase in non-human primate brain with [18F]FNDP

    Soluble epoxide hydrolase (sEH) is a promising candidate positron emission tomography (PET) imaging biomarker altered in various disorders, including vascular cognitive impairment (VCI), Alzheimer’s disease (A...

    Yong Du, Il Minn, Catherine Foss, Wojciech G. Lesniak, Feng Hu… in EJNMMI Research (2020)

    Download PDF (2824 KB) View Article

  6. No Access

    Article

    177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy

    To develop a prostate-specific membrane antigen (PSMA)-targeted radiotherapeutic for metastatic castration-resistant prostate cancer (mCRPC) with optimized efficacy and minimized toxicity employing the β-parti...

    Sangeeta Ray Banerjee, Vivek Kumar… in European Journal of Nuclear Medicine and M… (2019)